Protalix BioTherapeutics Inc (PLX)
1.20
-0.01
(-0.83%)
USD |
NYAM |
Apr 25, 12:05
Protalix BioTherapeutics Enterprise Value: 64.08M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 64.08M |
| April 23, 2024 | 63.35M |
| April 22, 2024 | 61.89M |
| April 19, 2024 | 59.70M |
| April 18, 2024 | 58.24M |
| April 17, 2024 | 59.70M |
| April 16, 2024 | 58.97M |
| April 15, 2024 | 58.97M |
| April 12, 2024 | 61.89M |
| April 11, 2024 | 64.81M |
| April 10, 2024 | 67.74M |
| April 09, 2024 | 72.12M |
| April 08, 2024 | 70.66M |
| April 05, 2024 | 61.16M |
| April 04, 2024 | 64.08M |
| April 03, 2024 | 66.28M |
| April 02, 2024 | 66.28M |
| April 01, 2024 | 67.01M |
| March 28, 2024 | 67.74M |
| March 27, 2024 | 67.01M |
| March 26, 2024 | 64.81M |
| March 25, 2024 | 64.81M |
| March 22, 2024 | 68.47M |
| March 21, 2024 | 72.12M |
| March 20, 2024 | 73.58M |
| Date | Value |
|---|---|
| March 19, 2024 | 70.66M |
| March 18, 2024 | 68.47M |
| March 15, 2024 | 72.85M |
| March 14, 2024 | 75.77M |
| March 13, 2024 | 86.73M |
| March 12, 2024 | 80.16M |
| March 11, 2024 | 80.89M |
| March 08, 2024 | 84.54M |
| March 07, 2024 | 82.35M |
| March 06, 2024 | 83.81M |
| March 05, 2024 | 86.73M |
| March 04, 2024 | 90.38M |
| March 01, 2024 | 94.04M |
| February 29, 2024 | 94.60M |
| February 28, 2024 | 88.04M |
| February 27, 2024 | 89.50M |
| February 26, 2024 | 84.39M |
| February 23, 2024 | 81.47M |
| February 22, 2024 | 80.01M |
| February 21, 2024 | 79.28M |
| February 20, 2024 | 80.74M |
| February 16, 2024 | 82.93M |
| February 15, 2024 | 86.58M |
| February 14, 2024 | 83.66M |
| February 13, 2024 | 79.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.45M
Minimum
Dec 03 2021
274.11M
Maximum
Feb 24 2021
93.08M
Average
84.10M
Median
Jul 16 2019
Enterprise Value Benchmarks
| Agenus Inc | 104.17M |
| InfuSystems Holdings Inc | 196.22M |
| Corbus Pharmaceuticals Holdings Inc | 368.73M |
| AIM ImmunoTech Inc | 9.076M |
| Armata Pharmaceuticals Inc | 159.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.044M |
| Revenue (Quarterly) | 10.49M |
| Total Expenses (Quarterly) | 16.10M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 15.54% |
| Profit Margin (Quarterly) | -57.64% |
| Earnings Yield | 1.67% |
| Operating Earnings Yield | 11.21% |
| Normalized Earnings Yield | 1.667 |